Article and Video CATEGORIES
Several weeks ago I had the opportunity to discuss several difficult cases with experts Drs. Paul Hesketh from the Lahey Clinic outside of Boston and Karen Kelly from Kansas University Medical Center in Kansas City, KS. These scenarios raise questions about how best to manage lung cancer issues in elderly and/or frail patients, starting with a 78 year-old woman who presented to me for discussion of the pros and cons of post-operative therapy, which also touch on other factors of administering chemotherapy to more marginal patients in general, regardless of the setting.
Here are the audio and video versions of the podcast, along with the transcript and figures.
[powerpress]
adjuvant-therapy-in-frail-and-elderly-patients-hesketh-and-kelly-audio-podcast
adjuvant-therapy-in-frail-and-elderly-patients-hesketh-and-kelly-transcript
adjuvant-therapy-in-frail-and-elderly-patients-hesketh-and-kelly-figures
This program was made possible by an educational grant from OSI Pharmaceuticals, who had no input in any of its content. We thank them for their support.
Upcoming podcasts will cover discussions of elderly/poor performance status patients with locally advanced NSCLC and metastatic lung cancer.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…